The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The value of using next-generation flow cytometry to measure MRD status
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the value of using next-generation flow cytometry to measure measurable residual disease (MRD) status. Dr Paiva comments on the advantages of using next-generation technologies, including the high sensitivity of these methods, and the possibility of performing MRD measurements without a bone marrow sample. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
